With sufficient expertise in disease model establishment, Creative Biolabs provides a wide range of chronic kidney disease models, including surgical models, nephrotoxic models, and immune-mediated models, for investigators to evaluate potential novel therapeutics as well as to elucidate underlying mechanisms.

Chronic Kidney Disease (CKD)

Chronic kidney disease (CKD) is defined as the progressive loss of kidney function over a period of months or years, which is a worldwide public health problem with rising incidence and prevalence. The main pathologies of CKD are glomerulosclerosis, tubulointerstitial inflammation, and fibrosis. Animal models of CKD provide an opportunity to investigate disease-specific mechanisms, to investigate molecular pathogenesis, and to assess potential novel therapies. Among the various models, adriamycin nephropathy (AN) is a rodent model of CKD that has been studied extensively and has greatly contributed to the understanding of the mechanisms underlying the progression of the chronic proteinuric renal disease.

Adriamycin Nephropathy (AN) Rodent Model

Adriamycin was first discovered to elicit renal failure in 1977. At present, adriamycin is a well-known inducer of renal injury and thus is frequently used to mimic human minimal lesion nephrotic syndrome and focal glomerular sclerosis (FGS). Typical pathophysiological features include glomerular injury, proteinuria, renal fibrosis and inflammatory cell infiltration, making this model attractive as an in vivo drug screening system.

Adriamycin nephropathy has several advantages when used as an experimental model of CKD. Firstly, it is highly reproducible with the consistent and predictable timing of injury. Secondly, it is a robust model with severe degree of injuries but acceptable mortality (<5%) and morbidity (weight loss). Last but not least, both rat and mouse models of adriamycin nephropathy are well characterized. Limitations still exist such as the requirement of operator skills to perform the intravenous injection of the testing drug.

Adriamycin-Induced Nephropathy (AN) Rodent ModelFig.1 Nitro-oleic acid (OA-NO2) ameliorates albuminuria in adriamycin (ADR) nephropathy. (Liu et al. 2013)

Creative Biolabs provides all kinds of assessments for testing the effectiveness of potential drugs depending on your research objectives, including but not limited to:

  • Body Weight
  • Kidney Weight
  • Measurement of Proteinuria and Creatinine
  • Immunohistochemical Examination
  • Biomarker Analysis
  • Confocal Microscopy Analysis

Meanwhile, Creative Biolabs also offers other types of rodent urological disease models that you may be interested in:

Please feel free to contact us for information on the models listed above or if you would like to propose a new model or customize an existing model to meet your particular research needs. At Creative Biolabs, continued communication during on-going studies and progress report are guaranteed for the collection of clinically reliable and relevant data.

Reference

  1. Liu, S.; et al. Nitro-oleic acid protects against adriamycin-induced nephropathy in mice[J]. Am J Physiol Renal Physiol. 2013, 305(11): F1533-F1541.

For lab research use only.



Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-357-2254
Fax: 1-631-207-8356
Email:
Europe
UK - Germany
Email:

Follow us on:
Copyright ©2011 - 2020 Creative Biolabs.